{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T22:31:38Z","timestamp":1770071498679,"version":"3.49.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oper Orthop Traumatol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00064-025-00925-6","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T11:20:55Z","timestamp":1769167255000},"page":"23-32","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypertherme isolierte Extremit\u00e4tenperfusion mit TNF-alpha und Melphalan bei lokal fortgeschrittenen Weichgewebesarkomen","Hyperthermic isolated limb perfusion with TNF-alpha and melphalan for the treatment of locally advanced soft-tissue sarcoma"],"prefix":"10.1007","volume":"38","author":[{"given":"Lars Erik","family":"Podleska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jendrik","family":"Hardes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arne","family":"Streitb\u00fcrger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"T\u00e4ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"925_CR1","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1093\/annonc\/mdi229","volume":"16","author":"S Bonvalot","year":"2005","unstructured":"Bonvalot\u00a0S, Laplanche\u00a0A, Lejeune\u00a0F et\u00a0al (2005) Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better? Ann Oncol 16:1061\u20131068","journal-title":"Ann Oncol"},{"key":"925_CR2","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s10434-001-0566-7","volume":"8","author":"D Daryanani","year":"2001","unstructured":"Daryanani\u00a0D, Komdeur\u00a0R, Ter Veen\u00a0J et\u00a0al (2001) Continuous leakage measurement during hyperthermic isolated limb perfusion. Ann Surg Oncol 8:566\u2013572","journal-title":"Ann Surg Oncol"},{"key":"925_CR3","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1200\/JCO.1996.14.10.2653","volume":"14","author":"AM Eggermont","year":"1996","unstructured":"Eggermont\u00a0AM, Schraffordt Koops\u00a0H, Lienard\u00a0D et\u00a0al (1996) Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a\u00a0multicenter trial. J\u00a0Clin Oncol 14:2653\u20132665","journal-title":"J Clin Oncol"},{"key":"925_CR4","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s12957-020-02110-4","volume":"18","author":"F Farzaliyev","year":"2020","unstructured":"Farzaliyev\u00a0F, Touma\u00a0A, Taeger\u00a0G et\u00a0al (2020) Efficacy of hyperthermic isolated limb perfusion in the treatment of locally recurrent high-grade soft tissue sarcoma of the extremities. World J Surg Oncol 18:332","journal-title":"World J Surg Oncol"},{"key":"925_CR5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/jso.21724","volume":"103","author":"F Grabellus","year":"2011","unstructured":"Grabellus\u00a0F, Kraft\u00a0C, Sheu-Grabellus\u00a0SY et\u00a0al (2011) Tumor vascularization and histopathologic regression of soft tissue sarcomas treated with isolated limb perfusion with TNF-alpha and melphalan. J\u00a0Surg Oncol 103:371\u2013379","journal-title":"J Surg Oncol"},{"key":"925_CR6","doi-asserted-by":"publisher","first-page":"108050","DOI":"10.1016\/j.ejso.2024.108050","volume":"50","author":"AJ Hayes","year":"2024","unstructured":"Hayes\u00a0AJ, Coker\u00a0DJ, Been\u00a0L et\u00a0al (2024) Technical considerations for isolated limb perfusion: A\u00a0consensus paper. Eur J Surg Oncol 50:108050","journal-title":"Eur J Surg Oncol"},{"key":"925_CR7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/cpf.12164","volume":"35","author":"IF Paulsen","year":"2015","unstructured":"Paulsen\u00a0IF, Chakera\u00a0AH, Schmidt\u00a0G et\u00a0al (2015) Radionuclide leakage monitoring during hyperthermic isolated limb perfusion for treatment of local melanoma metastasis in an extremity. Clin Physiol Funct Imaging 35:301\u2013305","journal-title":"Clin Physiol Funct Imaging"},{"key":"925_CR8","volume-title":"Extremity volume calculation tool","author":"LE Podleska","year":"2013","unstructured":"Podleska\u00a0LE (2013) Extremity volume calculation tool"},{"key":"925_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12957-017-1150-3","volume":"15","author":"LE Podleska","year":"2017","unstructured":"Podleska\u00a0LE, Kaya\u00a0N, Farzaliyev\u00a0F et\u00a0al (2017) Lower limb function and quality of life after ILP for soft-tissue sarcoma. World J Surg Oncol 15:84","journal-title":"World J Surg Oncol"},{"key":"925_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1477-7819-12-81","volume":"12","author":"LE Podleska","year":"2014","unstructured":"Podleska\u00a0LE, Poeppel\u00a0T, Herbrik\u00a0M et\u00a0al (2014) Drug dosage in isolated limb perfusion: evaluation of a\u00a0limb volume model for extremity volume calculation. World J Surg Oncol 12:81","journal-title":"World J Surg Oncol"},{"key":"925_CR11","doi-asserted-by":"publisher","first-page":"112949","DOI":"10.1016\/j.ejca.2023.112949","volume":"190","author":"SJM Reijers","year":"2023","unstructured":"Reijers\u00a0SJM, Davies\u00a0E, Grunhagen\u00a0DJ et\u00a0al (2023) Variation in response rates to isolated limb perfusion in different soft-tissue tumour subtypes: an international multi-centre study. Eur J Cancer 190:112949","journal-title":"Eur J Cancer"},{"key":"925_CR12","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/0277-5379(82)90235-8","volume":"18","author":"J Wieberdink","year":"1982","unstructured":"Wieberdink\u00a0J, Benckhuysen\u00a0C, Braat\u00a0RP et\u00a0al (1982) Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 18:905\u2013910","journal-title":"Eur J Cancer Clin Oncol"},{"key":"925_CR13","doi-asserted-by":"crossref","unstructured":"De Wilt JH, Ten Hagen TL, De Boeck G et al. (2000) Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 82:1000\u20131003","DOI":"10.1054\/bjoc.1999.1032"}],"container-title":["Operative Orthop\u00e4die und Traumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00064-025-00925-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00064-025-00925-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00064-025-00925-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T10:47:50Z","timestamp":1770029270000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00064-025-00925-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["925"],"URL":"https:\/\/doi.org\/10.1007\/s00064-025-00925-6","relation":{},"ISSN":["0934-6694","1439-0981"],"issn-type":[{"value":"0934-6694","type":"print"},{"value":"1439-0981","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"L.E.\u00a0Podleska war in der Vergangenheit als wissenschaftlicher Berater f\u00fcr die Firma Belpharma t\u00e4tig. J.\u00a0Hardes, A.\u00a0Streitb\u00fcrger und G.\u00a0T\u00e4ger geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}